Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00641732 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,045
- Enrollment target
NCT00641732 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 1,045 participants.
The verdict
NCT00641732, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,045 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
Interventions
- DRUG TAK-442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,045 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00641732
The ClinicalTrials.gov registry entry for NCT00641732 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,045 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-442 is the first listed.
NCT00641732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00641732 about?
NCT00641732 is a clinical study titled "Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement". The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
What is the current status of trial NCT00641732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,045 participants. The study started on 2007-10. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00641732?
The interventions under investigation include: TAK-442 (DRUG).
Who is sponsoring clinical trial NCT00641732?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.